Keyphrases
Interferon-γ
100%
Erythema multiforme
100%
Interleukin-15 (IL-15)
100%
Janus Kinase Inhibitors
100%
Tofacitinib
50%
Biopsy Specimen
20%
Upadacitinib
20%
Effective Therapy
10%
Consecutive Patients
10%
Tertiary Care Hospital
10%
RNA Sequencing (RNA-seq)
10%
Treatment Strategy
10%
Cytokine Expression
10%
RNA-seq Analysis
10%
Once-daily
10%
Female Patients
10%
Twice Daily
10%
Retrospective Case Series
10%
Clinical Improvement
10%
Disease Duration
10%
Hybrid Analysis
10%
Median Range
10%
Proteomic Analysis
10%
Change of Measure
10%
Intervention Therapy
10%
Multiple Treatments
10%
Lesional Skin
10%
Healthy Skin
10%
RNA Fluorescence in Situ Hybridization (RNA-FISH)
10%
Molecular Findings
10%
Skin Biopsy Specimens
10%
Dermatology Clinic
10%
Historic Samples
10%
Biochemistry, Genetics and Molecular Biology
Interferon Gamma
100%
Janus Kinase
100%
Interleukin 15
100%
Tofacitinib
100%
Cytokine
80%
RNA Sequence
40%
Upregulation
20%
RNA
20%
Mediator
20%
Janus Kinase Inhibitor
20%
In Situ Hybridization
20%
Glucocorticoid
20%
Proteomics
20%
Medicine and Dentistry
Janus Kinase
100%
Gamma Interferon
100%
Interleukin 15
100%
Erythema Multiforme
100%
Tofacitinib
50%
Cytokine
40%
RNA Sequence
20%
Biopsy Technique
20%
Upadacitinib
20%
Patient Referral
10%
Mediator
10%
Upregulation
10%
Disease Duration
10%
Dermatology
10%
Glucocorticoid
10%
Skin Biopsy
10%
Janus Kinase Inhibitor
10%
In Situ Hybridization
10%
Diseases
10%
Proteomics
10%
Pharmacology, Toxicology and Pharmaceutical Science
Janus Kinase
100%
Gamma Interferon
100%
Erythema Multiforme
100%
Interleukin 15
100%
Tofacitinib
50%
Cytokine
40%
RNA-Sequencing
20%
Upadacitinib
20%
Glucocorticoid
10%
Disease Duration
10%
Janus Kinase Inhibitor
10%
Diseases
10%